Affiliation:
1. PMI R&D, Philip Morris Products S.A.,
Abstract
Abstract
In medical applications, inhalable drugs are commonly delivered as aerosols in which the drug is i) the only bioactive constituent and ii) confined to the particulate fraction. For these low complexity aerosols, there are indications that in vitro exposure at the air-liquid interface (ALI) does not increase in vitro-in vivo translatability compared to the less complex and more controlled exposures under submerged conditions. We characterized aerosol delivery within the Vitrocell® Cloud 24 an in vitro aerosol exposure system frequently used for conducting ALI exposures—and used the system to test the hypothesis that there are no relevant differences between exposure modes. Cultures of the human adenocarcinoma-derived cell line A549 were exposed to bortezomib, anatabine, or the selective IκB kinase IKK-16, either in submerged state or at the ALI. The drugs’ toxicities and efficacies to counteract an induced pre-inflammatory state were compared between the exposure modes. The impact of the complexity of the biological test system was investigated by including ALI exposures of organotypic bronchial epithelial cultures. Our results demonstrate that i) the Vitrocell® Cloud 24 is useful for conducting controlled aerosol exposures and ii) ALI and submerged exposures are not equivalent.
Publisher
Research Square Platform LLC
Reference15 articles.
1. Constant S, Wiszniewski L, Huang S. The Use of in vitro 3D Cell Models of Human Airway Epithelia (MucilAirTM) in Inhalation Toxicity. In: Haycock J, Ahluwalia A, Wilkinson JM, editors. Cellular In Vitro Testing: Methods and Protocols. Singapore: Jenny Stanford Publishing; 2014.
2. SEURAT: safety evaluation ultimately replacing animal testing—recommendations for future research in the field of predictive toxicology;Daston G;Arch Toxicol,2015
3. Why endocrine disrupting chemicals (EDCs) challenge traditional risk assessment and how to respond;Fuhrman VF;J Hazard Mat,2015
4. Human lung epithelial cell cultures for analysis of inhaled toxicants: Lessons learned and future directions;Hiemstra PS;Toxicol In Vitro,2018
5. Lessons from toxicology: developing a 21st-century paradigm for medical research;Langley G;Environ Health Perspect,2015